SCHEMBL1418236

SCHEMBL1418236

C=CC(=O)Nc1cc2c(Nc3cccc(Br)c3)ncnc2cc1OCCCN1CCOC(=O)C1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 20/20 0.83
ERBB2 P04626 4/20 0.83
KDR P35968 4/20 0.62
KIT P10721 2/20 0.62
SRC P12931 2/20 0.62
ERBB3 P21860 2/20 0.62
ERBB4 Q15303 2/20 0.62
BMPR1B O00238 1/20 0.62
CIT O14578 1/20 0.62
MAP2K7 O14733 1/20 0.62
GAK O14976 1/20 0.62
EPHB6 O15197 1/20 0.62
MAP3K7 O43318 1/20 0.62
RIPK2 O43353 1/20 0.62
STK17B O94768 1/20 0.62
STK10 O94804 1/20 0.62
ABL1 P00519 1/20 0.62
LCK P06239 1/20 0.62
FYN P06241 1/20 0.62
YES1 P07947 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995071 0.91 EGFR (1.00) EGFRERBB2KDRKITSRC
SCHEMBL29519908 0.91 EGFR (1.00) EGFRERBB2KDRKITSRC
SCHEMBL1419058 0.88 EGFR (0.65) EGFRERBB2KDRERBB4
SCHEMBL7686990 0.87 EGFR (0.74) EGFRERBB2KDRKITSRC
SCHEMBL7686992 0.87 EGFR (0.74) EGFRERBB2KDRKITSRC
SCHEMBL7687027 0.87 EGFR (0.74) EGFRERBB2KDRKITSRC
SCHEMBL14356869 0.87 EGFR (1.00) EGFRERBB2KDRKITSRC
SCHEMBL1417787 0.86 EGFR (0.86) EGFRERBB2KDRKITSRC
SCHEMBL4220151 0.84 KDR (0.66) EGFRERBB2KDRSRCERBB4
SCHEMBL1417945 0.83 EGFR (0.83) EGFRERBB2KDRKITSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322645-A2 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2003-07-02 EP claimed
US-6403580-B1 HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-11 US claimed
WO-2002018375-A1 QUINAZOLINES, MEDICAMENTS, WHICH CONTAIN THESE COMPOUNDS AND WHICH ARE EFFECTIVE AS TYROSINE KINASE INHIBITORS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-03-07 WO claimed
EP-2298746-A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-03-23 EP disclosed
US-6972288-B1 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-12-06 US disclosed
US-6403580-B1 HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-06-11 US disclosed
EP-1157011-A1 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES Boehringer Ingelheim Pharma KG (DE) 2001-11-28 EP disclosed
WO-2000051991-A1 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-08 WO disclosed